SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending following its Q4 earnings report, which, despite solid membership and ad revenue growth, was met with investor concern over a conservative Q1 outlook and the all-cash Warner Bros. Discovery acquisition proposal. The community is sharply divided, with many seeing the stock as oversold and a long-term buying opportunity, while others express fears of ongoing downside due to acquisition-related debt and a shift in company priorities. The market continues to weigh Netflix's content strategy and future growth trajectory amidst a competitive streaming landscape.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is a hot topic amidst a sharp divergence of investor sentiment, primarily driven by its ambitious AI infrastructure expansion and substantial debt. While some highlight its impressive cloud backlog and potential for major AI contracts, others are concerned about increased capital expenditures, recent revenue performance, and a bondholder lawsuit related to debt financing, leading to fervent debate about its future trajectory.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed Inc. is surging due to its subsidiary, Lucid Diagnostics, securing a significant contract with the U.S. Department of Veterans Affairs for its EsoGuard esophageal DNA test. This news has ignited intense discussion among traders, who are actively debating the potential for continued upside driven by its low float and the strategic importance of expanding esophageal cancer screening across the VA healthcare system, though some express skepticism given the company's past volatility.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is currently trending following a significant 10-year data center lease agreement with Riot Platforms, providing 25 megawatts of capacity with options for substantial expansion, signaling AMD's growing role in AI infrastructure. The community is highly optimistic, noting AMD's consistent strength even on broader market downturns and anticipating continued market share gains amidst surging demand for AI compute.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is generating significant discussion as the company reveals strategic progress with record 2025 production and deliveries, a new Rockwell Automation partnership for its Saudi facility, and a robotaxi alliance debut at CES. Despite these operational advancements, the stock faces intense investor scrutiny due to reports of seeking international funding beyond its primary backer and persistent dilution, driving strong volatility and concerns about its financial trajectory.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is experiencing a significant surge, driven by widespread anticipation surrounding its impending earnings report and recent analyst upgrades. The community is actively discussing the potential for a substantial short squeeze and a sustained upward trajectory, fueled by confidence in its manufacturing advancements and increasing AI server demand. While many foresee a strong breakout, others remain watchful for a 'sell the news' reaction after its impressive run.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is trending prominently amidst a flurry of community discussion ignited by its namesake's recent public statements, impacting market sentiment and international relations. A significant short interest is fueling debate among investors, with many anticipating a potential squeeze, while others raise concerns about the company's fundamentals and the ongoing political discourse.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit shares are trending lower following a recent analyst report citing softer ad agency feedback, which has sparked a rapid decline and fueled discussions around potential insider selling. Despite this, other analysts remain bullish on its growth prospects from AI data licensing and ad product innovation, leading to community debate on whether the current volatility presents a buying opportunity ahead of upcoming earnings or signals deeper concerns for the social media platform.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD, a leveraged inverse natural gas ETF, is trending due to extreme volatility in the natural gas market driven by severe cold weather forecasts across the U.S. This recently caused a dramatic price surge in natural gas, leading to a sharp decline in KOLD, prompting active community debate on whether the ETF has bottomed for a rebound or faces further downside, solidifying its 'Widowmaker' reputation.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is rallying sharply, primarily driven by President Trump's statements from Davos, which included a softened stance on Greenland and optimistic market outlook. The community is actively debating this rapid "V" shaped recovery, with many confidently buying dips amidst ongoing discussions about an "AI meltup" propelling the tech-heavy index despite some skepticism about market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 9.2% Higher - Still a Buy?

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Up 9.2% - Here's Why...

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Up 22.1% in December

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 49,429,420...

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 5.5% - Should You Sell?

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 5.5% - Should You Sell...

<ul class="summary-bullets"><li>The European study is expected to enroll 40 newly diagnosed AML patients.</li><li>Enrollment at U.S. sites is planned to begin in the first quarter of 2026, with European enrollment anticipated in the second quarter of 2026, the company said.</li><li>SLS stock is on track to end in the red in five of the last seven sessions.</li></ul>SELLAS Life Sciences Group Inc (SLS) stock was in the spotlight after it signed an agreement with IMPACT-AML (Acute Myeloid Leukemia) to expand the clinical development of SLS009, a targeted cancer therapy, into Europe.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> has been trending down lately and is on track to end in the red in five of the last seven sessions. It was trading 3.2% lower. Last week, investors booked profits amid dilution concerns after Sellas reported $26.5 million in proceeds from the exercise of common stock warrants, in addition to its estimated cash and cash equivalents of $71.8 million as of December-end.<h2 class="st-heading-2">IMPACT-AML Tie Up</h2>The IMPACT-AML, a pan-European initiative within the EU Mission Cancer program, will conduct a European clinical study evaluating SLS009, providing SELLAS access to multiple clinical sites and a broader patient population. SELLAS aims to leverage the partnership to accelerate enrollment, expand patient access to SLS009, and maintain cost efficiency, it added.The European study is expected to enroll 40 newly diagnosed AML patients with high-risk features to evaluate SLS009 in combination with azacitidine and venetoclax, medications to treat cancer. Enrollment at U.S. sites is planned to begin in the first quarter of 2026, with European enrollment anticipated in the second quarter of 2026, the company said.<h2 class="st-heading-2">Retail Chatter</h2>Despite the intraday decline, retail sentiment on Stocktwits remained in the ‘bullish’ zone over the past 24 hours, amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/SLS_jpg_8c87a5394f.webp" alt="SLS.jpg">One user saw the IMPACT-AML development as a positive for the stock and wondered why bears were still selling.<stembedurl>https://stocktwits.com/insidersruleloosersdrool/message/641795770</stembedurl>Another user said validating SLS009 in both the U.S. and the EU simultaneously makes the drug more attractive to a global buyer like Novartis.<stembedurl>https://stocktwits.com/Cresskill198/message/641779078</stembedurl>SLS shares have shot up 345% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-ibrx-stock-gain-retail-attention-today/cmULjP5R4eA">IBRX Stock Finds Retail Cheer After Company’s Immunotherapy For Bladder Cancer Gets Saudi FDA Approval</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of stock price falling. (Photo by Yuichiro Chino/Getty Images)

SLS Stock In Spotlight On EU Expansion For Cancer Therapy – Retail Says Potential Catalyst For Buyout

The IMPACT-AML program will conduct a European clinical study evaluating SLS009 and provide SELLAS access to multiple clinical sites and a broader patient population.

Equity

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Up 10.3% - Here's What Happened

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 10.3% Higher - Time to Buy...

<ul class="summary-bullets"><li>On Thursday, Sellas said that it received approximately $26.5 million in proceeds from the exercise of common stock warrants.</li><li>SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy.</li><li>The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred.</li></ul>Shares of SELLAS Life Sciences Group, Inc. (SLS) fell for the fourth straight session on Friday as investors resorted to profit taking amid dilution concerns.Shares of the company traded 13% lower at $3.34 at the time of writing, after <a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-breaches-5-dollar-level-after-over-3-years/cmxuTsiR4RS">breaching</a> the $5 threshold for the first time in over three years earlier this week.On Thursday, Sellas said that it received approximately $26.5 million in proceeds from the exercise of common stock warrants. This is in addition to the company’s estimated cash and cash equivalents of $71.8 million as of December-end.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SLS stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.A Stocktwits user expressed disappointment at the company diluting shares of the company by exercising warrants provided it has “sufficient cash” to carry out ongoing trials. However, they expect the price to be back up by February.<stembedurl>https://www.stocktwits.com/jackobull/message/641370638</stembedurl>Another, however, said that there is no “legitimate reason” to sell the stock. “...we longs know this is short lived. &nbsp;VERY short lived. &nbsp;It will explode upward from this oversold action,” they wrote.<stembedurl>https://www.stocktwits.com/Wut_About_Bob/message/641368167</stembedurl><h2 class="st-heading-2"> What Drove The Recent Rally?</h2>SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy. AML is a fast-growing cancer of the blood and bone marrow where immature white blood cells build up, crowding out healthy cells, leading to fatigue, infections, and bleeding.The ongoing GPS trial is an overall survival study, and final analysis is expected once 80 deaths have occurred. As of December 26, 72 deaths have occurred, the company <a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-group-stock-soars-as-it-nears-final-analysis-in-cancer-study/cL7dROARExt">said</a> last month, highlighting that it had previously expected 80 patient deaths to occur by December end.“While the 80th event has not yet occurred, and we remain fully blinded, every passing month may increase the probability of a successful study as highlighted by key opinion leaders in our recent R&amp;D event. Conclusive data will follow the unblinding and analyses of the study results,” SELLAS CEO Angelos Stergiou said at the time. The announcement kickstarted a rally that mostly sustained through late December and early January.Last week, Maxim analyst Jason McCarthy noted that delays in an event-driven trial like SELLAS’ could be suggestive of extended survival benefit from GPS.Besides GPS, SELLAS has another experimental drug in its pipeline called SLS009 also being developed to target certain cancers.According to data from Koyfin, all three of the analysts covering SELLAS rate it ‘Buy’ or higher. The stock has an average price target of $6.83, hinting at significant potential upside.<a href="https://stocktwits.com/symbol/SLS">SLS shares</a> have nearly tripled over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/kalvista-pharmaceuticals-stock-rallies-after-hours-on-strong-genetic-disorder-drug-sales-kickstart/cmUbnxGR45Z">KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

SELLAS Life Sciences Falls For Fourth Straight Session — What’s Driving The Sell Off?

Shares of the company traded 13% lower at $3.34 at the time of writing.

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 8.4% - Here's Why

SELLAS Life Sciences Group (NASDAQ:SLS) Trading Down 8.4% - Here's Why...

<ul class="summary-bullets"><li>Headlines from CES reignited enthusiasm around AI hardware and autonomous tech.</li><li>Despite the dip, retail sentiment on Stocktwits toward SPY and QQQ remained bullish.&nbsp;</li></ul>U.S. stock futures were trading in the red early Tuesday as investors balance AI optimism from CES, while awaiting crucial jobs data later this week.As of 3:50 a.m. ET on Tuesday, Nasdaq 100 futures and S&amp;P 500 futures fell 0.1%, and the Dow futures fell 0.2%, while Russell 2000 futures fell 0.4%.On Stocktwits, however, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has remained ‘bullish’, amid normal message volumes.Trending Stocks To Watch Nvidia (NVDA):&nbsp;At CES, Jensen Huang&nbsp;announced Nvidia’s next-generation AI chips, Vera Rubin, a successor to&nbsp;its Blackwell architecture, which would go on sale in the second half of the year. It is also joining the push to develop self-driving cars, reinforcing its position as a full-stack AI platform company, not just a chipmaker.&nbsp; Tesla (TSLA): CEO Elon Musk downplayed concerns around Nvidia’s newly unveiled Alpamayo autonomous driving AI.&nbsp; Advanced Micro Devices, Inc. (AMD)&nbsp;garnered retail attention on Stocktwits after the chipmaker&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amd-crashes-ces-2026-with-all-out-offensive-against-nvidia/cmxwVexR4Tb">launched</a> a slew of AI chips for computers, data centers, and gaming at the CES trade show in Las Vegas. Intel (INTC)&nbsp;unveiled its latest laptop processors, the Core Ultra Series 3, which are set to roll out in new computers later this month. Also, keep an eye on Chevron (CVX), Exxon Mobil Corp (XOM), amid political developments in Venezuela. OneStream (OS):&nbsp;HG Capital is reportedly nearing a deal to acquire the financial software firm.&nbsp; Sellas Lifesciences (SLS)&nbsp;is the top trending ticker on Stocktwits at the time of writing.&nbsp; Aeva (AEVA)&nbsp;is on the retail radar after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tiny-lidar-player-aeva-stock-rockets-over-25-after-hours-on-nvidia-deal/cmxwXUUR4RV">announcing</a> its 4D LiDAR will be integrated into the Nvidia Drive Hyperion platform. PLTR (Palantir) and&nbsp;RCAT (Red Cat Holdings) are trending. Traders are&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/red-cat-roars-back-venezuela-speculation-sends-drone-stock-flying/cmxw13MR4Rs">speculating</a> on increased contract awards for surveillance and drone technology.&nbsp; Zeta Global (ZETA)&nbsp;is gaining traction following the collaboration with OpenAI to enhance its marketing platform. And&nbsp;Alumis (ALMS) is scheduled to report topline Phase 3 data for envudeucitinib in plaque psoriasis before the open, with a conference call at 8:00 a.m. ET.&nbsp; Other noteworthy tickers trending on Stocktwits at the time of writing were Amazon (AMZN), Momentus In (MNTS), Bank of America (BAC), Alibaba (BABA), Paramount Skydance (PSKY), and Apteva Therapeutics (APVO) Other Catalysts To Watch With no significant economic releases due Tuesday, traders are expected to continue tracking CES developments and positioning ahead of key jobs data later this week. Siemens is expected to showcase its Industrial Metaverse, while Lenovo CEO is expected to unveil the “AI for All” strategy today. For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Edge Lower Despite CES-Driven AI Optimism: Why NVDA, TSLA, AMD, AEVA, OS Are On Traders' Radar Today

Markets seem to be balancing CES-driven AI optimism with caution ahead of upcoming jobs data.

Markets seem to be balancing CES-driven AI optimism with caution ahead of upcoming jobs data this week.


<ul class="summary-bullets"><li>SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia.</li><li>The stock has had a good run since the company said that slower deaths in the GPS trial might imply further clinical benefit.</li></ul>Shares of SELLAS Life Sciences Group, Inc. (SLS) garnered retail attention on Monday after it breached the $5 threshold after over three years during the day trading session.The stock closed 15% higher in the regular trading session to close at $5 and traded 2% higher after hours.<h2 class="st-heading-2">Retail Speaks</h2>On Stocktwits, retail sentiment around SLS stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume improved from ‘extremely low’ to ‘low’ levels.A bullish Stocktwits user rejoiced at the new levels.<stembedurl>https://www.stocktwits.com/Duncan74/message/640892449</stembedurl>Another expressed optimism for a buyout of the company for as much as $25 billion.<stembedurl>https://www.stocktwits.com/Mjohns92/message/640889738</stembedurl><h2 class="st-heading-2">What’s Driving The Rally?</h2>SELLAS is currently <a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-group-stock-soars-as-it-nears-final-analysis-in-cancer-study/cL7dROARExt">evaluating</a> Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy. AML is a fast-growing cancer of the blood and bone marrow where immature white blood cells build up, crowding out healthy cells, leading to fatigue, infections, and bleeding.The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred. As of December 26, 72 deaths have occurred, the company said last month, highlighting that it had previously expected 80 patient deaths to occur by December end.“While the 80th event has not yet occurred, and we remain fully blinded, every passing month may increase the probability of a successful study as highlighted by key opinion leaders in our recent R&amp;D event. Conclusive data will follow the unblinding and analyses of the study results,” SELLAS CEO Angelos Stergiou then said.Last week, Maxim analyst Jason McCarthy noted that delays in an event-driven trial like SELLAS’ could be suggestive of extended survival benefit from GPS.Besides GPS, SELLAS has another experimental drug in its pipeline called SLS009 also being developed to target certain cancers.According to data from Koyfin, all three of the analysts covering SELLAS rate it ‘Buy’ or higher. The stock has an average price target of $6.83, hinting at further potential upside.<a href="https://stocktwits.com/symbol/SLS">SLS shares</a> have nearly tripled this year and multiplied by about five times in value over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/crnx-stock-gains-nbix-shares-drop-on-positive-results-from-genetics-disorder-trial/cmxMxA1R4Rf">CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

SLS Stock Breaches $5 Level After Over 3 Years: Retail Now Eyes Buyout For As Much As $25B 

SELLAS Life Sciences closed 15% higher in the regular trading session to close at $5 and traded 1% higher after hours.

SLS Stock Breaches $5 Levels After Over 3 Years: Retail Now Eyes Buyout For As Much As $25B 

SELLAS Life Sciences closed 15% higher in the regular trading session to close at $5 and traded 1% higher after hours.


SELLAS Life Sciences Group (NASDAQ:SLS) Sets New 52-Week High - Should You Buy?

SELLAS Life Sciences Group (NASDAQ:SLS) Reaches New 12-Month High - Should You Buy...

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Stocktwits

Stocktwits Polls

Traders are actively speculating on a potential acquisition by a major pharmaceutical company, with rumored valuations reaching up to $40 billion, driven by Big Pharma's need to fill patent expiration gaps.

High short interest and diminishing share availability are fueling strong sentiment for a 'GME style' short squeeze, as many anticipate shorts will be forced to cover at much higher prices.

Optimism surrounds the Phase 3 REGAL trial, which is extending beyond initial projections, suggesting a remarkable overall survival rate for patients and signaling strong efficacy for GPS.

Anticipation is building for a dual impact from upcoming news: crucial updates on the REGAL trial and the imminent 'first patient dosed' announcement for the SLS009 program, potentially propelling the stock higher.

Current Price	$4.32
Prev Close	$4.32
Open	$4.32
Dividend Yield	0.00%
50-Day Moving Average	$2.47
Beta	0.90
Avg. Volume	8.67M
PE Ratio	-15.06

52-Week High	$5.18
52-Week Low	$0.8505
Market Capitalization	$615.35M
EPS (Annual)	-$0.5046
Price to Book	11.84
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

SLS
SELLAS Life Sciences Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLS News

SLSSELLAS Life Sciences Group Inc